Influenza virus vaccine - Japan Vaccine/Terumo

Drug Profile

Influenza virus vaccine - Japan Vaccine/Terumo

Alternative Names: VN 100 - Japan Vaccine/Terumo

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company; Japan Vaccine; Kitasato Daiichi Sankyo Vaccine; Terumo
  • Class Influenza virus vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Influenza virus infections

Most Recent Events

  • 01 Mar 2016 Daiichi Sankyo completes a phase III trial in Influenza virus infections (In children, Prevention) in Japan (Intradermal) (JapicCTI-152991)
  • 10 Apr 2015 Preregistration for Influenza virus infections (Prevention) in Japan (Intradermal)
  • 23 Feb 2012 Early research in Infections (prevention) in Japan (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top